Guardant Health, Inc. (NASDAQ:GH) Receives $48.21 Average PT from Analysts

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) has been assigned an average rating of "Buy" from the nineteen research firms that are covering the firm, MarketBeat.com reports. Nineteen research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued a report on the stock in the last year is $48.21.

A number of research firms recently issued reports on GH. Piper Sandler upped their price target on shares of Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Canaccord Genuity Group upped their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Scotiabank boosted their price objective on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. The Goldman Sachs Group raised their price objective on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Raymond James reissued an "outperform" rating and set a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company's stock, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 2,668 shares of company stock valued at $95,208. Company insiders own 5.50% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Guardant Health

Several institutional investors have recently bought and sold shares of GH. NewEdge Advisors LLC lifted its stake in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares during the period. Summit Investment Advisors Inc. lifted its position in Guardant Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock worth $377,000 after acquiring an additional 391 shares during the period. Arizona State Retirement System grew its stake in Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after purchasing an additional 403 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company's stock valued at $102,000 after purchasing an additional 796 shares during the period. Finally, Jones Financial Companies Lllp increased its holdings in shares of Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after purchasing an additional 817 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Up 1.9 %

NASDAQ GH traded up $0.78 during trading hours on Friday, reaching $41.52. The company's stock had a trading volume of 1,588,988 shares, compared to its average volume of 2,472,813. Guardant Health has a 1 year low of $15.81 and a 1 year high of $50.89. The company has a market capitalization of $5.12 billion, a price-to-earnings ratio of -11.67 and a beta of 1.32. The firm's 50-day moving average price is $41.28 and its 200-day moving average price is $32.09.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Equities research analysts anticipate that Guardant Health will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.